Neurological complications of cardiovascular drugs

Handb Clin Neurol. 2021:177:319-344. doi: 10.1016/B978-0-12-819814-8.00020-2.

Abstract

Cardiovascular drugs are used to treat arterial hypertension, hyperlipidemia, arrhythmias, heart failure, and coronary artery disease. They also include antiplatelet and anticoagulant drugs that are essential for prevention of cardiogenic embolism. Most neurologic complications of the cardiovascular drugs are minor or transient and are far outweighed by the anticipated benefits of treatment. Other neurologic complications are more serious and require early recognition and management. Overtreatment of arterial hypertension may cause lightheadedness or fatigue but often responds readily to dose adjustment or an alternative drug. Other drug complications may be more troublesome as in myalgia associated with statins or headache associated with vasodilators. The recognized bleeding risk of the antithrombotics requires careful calculation of risk/benefit ratios for individual patients. Many neurologic complications of cardiovascular drugs are well documented in clinical trials with known frequency and severity, but others are rare and recognized only in isolated case reports or small case series. This chapter draws on both sources to report the adverse effects on muscle, nerve, and brain associated with commonly used cardiovascular drugs.

Keywords: Adverse event; Anticoagulant; Antiplatelet; Arrhythmia; Cognitive impairment; Hypercholesterolemia; Hypertension; Myopathy; Neuropathy; Stroke.

MeSH terms

  • Cardiovascular Agents / therapeutic use*
  • Humans
  • Platelet Aggregation Inhibitors

Substances

  • Cardiovascular Agents
  • Platelet Aggregation Inhibitors